Elevance Health is a healthcare plan company located in Indiana, United States, which is part of the Healthcare sector, and is traded under the ticker ELV on the NYSE exchange.
Elevance Health stock last closed at $545.85, up 0.45% from the previous day, and has increased 22.58% in one year. It has overperformed other stocks in the Healthcare Plans industry by 0.14 percentage points. Elevance Health stock is currently +26.54% from its 52-week low of $431.38, and -3.77% from its 52-week high of $567.26.
There are currently 231.89M shares of ELV outstanding. The market cap of ELV is $126.57B. In the past 24 hours, 724,664 ELV shares were traded.
You will need a brokerage account in order to access the NYSE market and buy ELV stock.
Based on our analysis, eToro is the best brokerage. Here's why:
Get $10 towards your purchase of shares by signing up for an account with eToro today.
Open eToro AccountNow that you've chosen the right brokerage, the next step is to fill out some personal details so you are able to buy ELV stock today.
Now that you have created your account on one of the best stock apps, you need to deposit funds:
Watch the tutorial below to see the process of transferring funds into your investment account.
After you have identified the best place to buy Elevance Health stock, it's crucial to research their stock prior to investing, so you actually understand the risk as well as the opportunity.
WallStreetZen was created to help part-time investors do better fundamental analysis quickly.
You can see all of the due diligence checks on ELV's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge ELV's intrinsic value.
Using relative valuations metrics:
You can access more valuation research on ELV's stock here.
Out of 13 Wall Street analysts who monitor ELV, the consensus analyst rating on ELV is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
Ben Hendrix, a top 5% analyst from RBC Capital maintains ELV with a buy rating and raises their ELV price target from $575.00 to $585.00, on Jul 18, 2024.
Kevin Fischbeck, a bottom 12% analyst from Bank of America downgrades ELV to a hold rating and lowers their ELV price target from $646.00 to $530.00, on Jul 18, 2024.
David S Macdonald, a top 4% analyst from Truist Securities maintains ELV with a strong buy rating and raises their ELV price target from $600.00 to $620.00, on Jul 15, 2024.
Truist Securities's David S Macdonald raised their price target on Elevance Health (NYSE: ELV) by 3.3% from $600 to $620 on 2024/07/15. The analyst maintained their Strong Buy rating on the stock.
Macdonald's price target hike was part of a pre-print review of names in their Healthcare Services coverage area.
The analyst told investors that the sector offers "attractive core demand drivers," M&A opportunities, and solid relative positioning.
Although "ongoing selectivity" is crucial, Macdonald said they are nevertheless optimistic about long-term drivers, which include demographics, the shift to value-based care, and the redirection of service sites.
The analyst believes those "long-term drivers" will support healthy expansion in the group.
Regarding Elevance Health, Macdonald believes that Elevance Health's partnership with Clayton and Dubilier & Rice, which was signed on 2024/04/15, is "a meaningful growth opportunity paving the way for further downside risk penetration."
Elevance Health will report its Q2 2024 earnings on 2024/07/17.
Yahoo Finance reports that the current consensus EPS estimate for the company's Q2 is $10.01 which, if achieved, would represent a 10.73% increase over Q2 2023's $9.04.
Erin Wright, a top 4% analyst from Morgan Stanley initiates coverage on ELV with a strong buy rating and announces their ELV price target of $643.00, on Jun 24, 2024.
Lisa Gill, a top 18% analyst from JP Morgan maintains ELV with a strong buy rating and raises their ELV price target from $628.00 to $631.00, on May 30, 2024.
You can dive deeper into what analysts are saying on the Elevance Health stock forecast page.
Last year, ELV earnings were $6.69B. During the past five year, ELV's earnings have gone up by 12.68% per year. This was faster than the Healthcare Plans industry average of 4.59%.
Last year, ELV revenue was $171.96B. Over the last five year, ELV's revenue has increased by 12.19% per year. This was slower than the Healthcare Plans industry average of 12.92%.
Dig into ELV's earnings and revenue performance here.
In the last 12 months, insiders at ELV have sold more shares than they have bought.
Ramiro G. Peru, Director of ELV, was the latest ELV insider to sell. They sold $400,234.56 worth of ELV shares on Aug 5, 2024.
Get more info about who owns ELV shares here.
Elevance Health pays a dividend of 1.17%, compared to the Healthcare Plans industry's average dividend yield of 1.85%. If you owned $1,000 worth of ELV stock, you would have received $11.67 in the past 12 months.
Elevance Health dividend payments have consistently grown over the past decade and have remained stable.
Find more analysis about Elevance Health dividend yield and history here.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
You have two main order types:
Click the Open button and your broker will execute the order.
If you need more info about buying stocks on eToro, click the helpful video below:
Now that you own some shares in ELV, you'll want to keep up with your new company.
Make a watchlist to get alerted to the latest events about your ELV stock.
To reiterate, here are the 6 steps to buy stock in Elevance Health:
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Elevance Health, create your watchlist below.